First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
被引用次数：596 相关文章

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for …

A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> This multicenter phase II study was
undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced …

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

A Inoue, K Kobayashi, K Usui… - Journal of clinical …, 2009 - pubmed.ncbi.nlm.nih.gov
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) …
[PDF] researchgate.net

[PDF][PDF] First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for …

A Inoue, K Kobayashi, K Usui, M Maemondo… - J Clin …, 2009 - researchgate.net
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

[引用][C] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for …

A INOUE, K KOBAYASHI, H MIYAZAWA… - Journal of clinical …, 2009 - pascal-francis.inist.fr
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring
Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy CNRS Inist …

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

A Inoue, K Kobayashi, K Usui… - Journal of Clinical …, 2009 - europepmc.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) …

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

K Kobayashi, A Inoue, K Usui… - Journal of Clinical …, 2009 - tohoku.elsevierpure.com
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) …

[引用][C] First-line gefitinib for patients with-advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for …

A INOUE - J Clin Oncol, 2009 - cir.nii.ac.jp
First-line gefitinib for patients with-advanced non-small-cell lung cancer harboring
epidermal growth factor receptor mutations without indication for chemotherapy | CiNii …